Pediatric Primary and Secondary Hyperlipidemias

[1]  G. Watts,et al.  Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. , 2018, Atherosclerosis.

[2]  Andrew A. Li,et al.  Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD , 2018, Diseases.

[3]  B. Nordestgaard,et al.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias? , 2018, Current Cardiology Reports.

[4]  E. Levy,et al.  Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. , 2018, The Journal of nutritional biochemistry.

[5]  M. Arca,et al.  The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study , 2018, Expert review of cardiovascular therapy.

[6]  C. Borghi,et al.  Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia , 2018, Expert opinion on drug metabolism & toxicology.

[7]  J. Heinecke,et al.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions? , 2018, Expert review of proteomics.

[8]  R. Hegele,et al.  The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. , 2017, The Canadian journal of cardiology.

[9]  D. Gaudet,et al.  Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. , 2017, Journal of clinical lipidology.

[10]  M. Ogura.  PCSK9 inhibition in the management of familial hypercholesterolemia. , 2018, Journal of cardiology.

[11]  K. Adeli,et al.  Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment , 2017, EJIFCC.

[12]  G. Norata,et al.  Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives , 2017, Vascular health and risk management.

[13]  I. Jialal,et al.  Modern Management of Familial Hypercholesterolemia. , 2016, Metabolic syndrome and related disorders.

[14]  E. Turner,et al.  Universal Cholesterol Screening in Childhood: A Systematic Review. , 2016, Academic pediatrics.

[15]  C. Blum.  Type III Hyperlipoproteinemia: Still Worth Considering? , 2016, Progress in cardiovascular diseases.

[16]  C. McNeal.  Lipoprotein(a): Its relevance to the pediatric population. , 2015, Journal of clinical lipidology.

[17]  H. Te,et al.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis , 2015, Clinical lipidology.

[18]  G. Lewis,et al.  New Insights into the Regulation of Chylomicron Production. , 2015, Annual review of nutrition.

[19]  E. Levy.  Insights from human congenital disorders of intestinal lipid metabolism , 2015, Journal of Lipid Research.

[20]  G. Schmitz,et al.  Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects , 2015, Clinical Research in Cardiology Supplements.

[21]  D. Nair,et al.  HDL genetic defects. , 2014, Current pharmaceutical design.

[22]  J. Tardif,et al.  Apolipoprotein B antisense inhibition--update on mipomersen. , 2013, Current pharmaceutical design.

[23]  E. Levy,et al.  Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers , 2010, Orphanet journal of rare diseases.

[24]  J. Dufour,et al.  Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. , 2008, Swiss medical weekly.

[25]  J. Goudevenos,et al.  Combined Treatment with Fibrates and Small Doses of Atorvastatin in Patients with Mixed Hyperlipidemia , 2002, Current medical research and opinion.

[26]  O. Raitakari,et al.  Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. , 2001 .

[27]  T. Kurihara,et al.  Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. , 1993, Clinical therapeutics.

[28]  C. Velican,et al.  Study on the onset of atherosclerotic lesions in human coronary arteries. , 1979, Medecine interne.